Share Buyback
EKF Diagnostics Holdings plc has announced an extension to its share buyback program, intending to purchase up to an additional £1.0 million of its ordinary shares. The company has already bought back 1,844,000 ordinary shares at a weighted average price of 25.8 pence per share. This buyback includes the acquisition of 544,000 ordinary shares from Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, facilitated by Harwood, to maintain an indirect beneficial interest for Mr. Mills below 30%. Following these transactions, the total number of ordinary shares carrying voting rights will be 439,919,154.
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that following the completion of the buyback extension announced on 21 October 2025, a further extension to the additional share buyback programme announced on 21 May 2025 will be undertaken. The Company intends to conduct additional on-market purchases of purchases of its ordinary shares of 1p each ("Ordinary Shares") of up to a further c. £1.0m, pursuant to the authorities obtained at the Company's last annual general meeting held on 20 May 2025. The Ordinary Shares will be held in treasury.
Consequently, the Company announces that it has purchased a total of 1,844,000 Ordinary Shares at a weighted average price of 25.8 pence per Ordinary Share.
Aggregated information
| Date of purchase | 14 November 2025 | ||
|---|---|---|---|
| Number of Ordinary Shares purchased | 1,844,000 | ||
| Highest price paid per Ordinary Share | 25.8p | ||
| Lowest price paid per Ordinary Share | 25.8p | ||
| Volume weighted average price paid | 25.8p | ||
| Transaction details | |||
| Number of Ordinary Shares purchased | Transaction price (GBp) | Time of transaction | Trading venue |
| 1,100,000 | 25.8p | 12:11:59 | AIMX |
| 200,000 | 25.8p | 16:20:44 | AIMX |
| 544,000 | 25.8p | 16:24:28 | AIMX |
Total voting rights
Following the purchase, the Company's total issued share capital will consist of 449,093,790 Ordinary Shares, of which 9,174,636 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 439,919,154. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
PDMR dealing
As part of the buyback and within the above aggregate purchase, EKF acquired 544,000 Ordinary Shares in total at a price of 25.8 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). EKF acquired 181,333 and 362,667 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.
Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 129,725,000 Ordinary Shares.
Additional disclosures relating to this PDMR dealing are detailed below.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
| Julian Baines, Executive Chair | via Walbrook PR | |
| Gavin Jones, Chief Executive Officer | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | |
| Phil Davies / Oliver Platts | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 | |
| a) | Name | Christopher Mills |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | EKF Diagnostics Holdings plc |
| b) | LEI | 213800DXTF3EAUK1AR05 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 1 pence each |
| Identification code | GB0031509804 | |
| b) | Nature of the transaction | Disposal of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 25.8p | 544,000 | |
| d) | Aggregated information | |
| - Aggregated volume | n/a | |
| - Price | ||
| e) | Date of the transaction | 14 N ovember 2025 |
| f) | Place of the transaction | London Stock Exchange, AIMX |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.